Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:19:37 2024-05-16 pm EDT			5-day change	1st Jan Change
3.515 ^USD	-1.54%		-3.57%	-51.92%

May. 08	Top Premarket Gainers	MT
May. 08	Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	MT

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

January 05, 2022 at 07:00 am EST

Repare Therapeutics Inc. announced the appointment of Philip Herman as its EVP Commercial & New Product Development. Mr. Herman joins Repare from Y-mAbs Therapeutics, where he served as Chief Commercial Officer and led the successful launch of DANYELZA® (naxitamab).

Latest news about Repare Therapeutics Inc.

Top Premarket Gainers	May. 08	MT
Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	May. 08	MT
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition	Apr. 30	CI
Repare Therapeutics Inc. Announces Directorate Changes	Apr. 26	CI
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	Feb. 15	CI
HC Wainwright Adjusts Repare Therapeutics Price Target to $10 From $25, Maintains Buy Rating	Feb. 14	MT
Repare Therapeutics to Regain Global Rights to Oncology Therapy Camonsertib After Termination of Collaboration With Roche	Feb. 13	MT
Repare Therapeutics to Collaborate With Debiopharm on Potential Cancer Therapy	Jan. 05	MT
Repare Therapeutics Inc. and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer	Jan. 04	CI
Repare Therapeutics Inc.(NasdaqGS:RPTX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Transcript : Repare Therapeutics Inc. - Special Call	Nov. 15
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor	Nov. 15	CI
Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Piper Sandler Cuts Repare Therapeutics' Price Target to $25 From $30, Keeps Overweight Rating	23-10-16	MT
Transcript : Repare Therapeutics Inc. - Special Call	23-10-13
Repare Therapeutics Reports 'Positive Initial Data' From Trial for Lunresertib	23-10-13	MT
Repare Therapeutics Inc. Reports Positive Initial Data from Modules 1 and 2 of its Ongoing Phase 1 Mythic Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib, an ATR Inhibitor	23-10-13	CI
Stifel Raises Repare Therapeutics' Price Target to $17 From $16, Keeps Buy Rating	23-09-25	MT
Transcript : Repare Therapeutics Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 11:30 AM	23-09-13
HC Wainwright Adjusts Price Target on Repare Therapeutics to $25 From $26, Keeps Buy Rating	23-08-17	MT
Repare Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Transcript : Repare Therapeutics Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 02:00 PM	23-06-14

Chart Repare Therapeutics Inc.

Duration

Period

More charts

Company Profile

Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Companyâs initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Sector

Biotechnology & Medical Research

Calendar

2024-06-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Repare Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.57 USD

Average target price

15.33 USD

Spread / Average Target

+329.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REPARE THERAPEUTICS INC.	-51.92%	152M
MODERNA, INC.	+33.51%	49.46B
IQVIA HOLDINGS INC.	+1.78%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.66%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.09%	18.64B
BIO-TECHNE CORPORATION	+7.89%	13.16B
MEDPACE HOLDINGS, INC.	+29.51%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.56%	12.1B

Other Biotechnology & Medical Research